Sandoz Sues FDA For Inaction On Omnitrope NDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Lawsuit seeks a court declaration that the 505(b)(2) pathway “can be used for protein-based biologic drugs regulated under Section 505 of the FD&C Act.”